What dose of CagriSema is used and how is it given?

Every vial at a glance.

Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
Vial3 mL of water
9.6 mg3.2 mg/mL: 0.25 mg is 7.8 units, 0.5 mg is 15.6 units, 1 mg is 31.3 units, 1.7 mg is 53.1 units, 2.4 mg is 75 units

No CagriSema label was located and Novo Nordisk calls it investigational,1 so the doses here are trial doses, such as cagrilintide 2.4 mg with semaglutide 2.4 mg once weekly, reached from 0.25 mg once weekly in 4-week steps in the 32-week phase 2 trial of Frias and colleagues (2023) in 92 adults with type 2 diabetes.23

What form CagriSema comes in

None of the sources retrieved gives a CagriSema vial strength, concentration, pen volume or mixing instruction. The 9.6 mg in 3 mL (3.2 mg/mL) behind the table above is the Wegovy FlexTouch pen, a semaglutide-alone label figure, so the rows are arithmetic and not a CagriSema strength.4

FormWhat the sources say
Solution for injectionThe EMA's paediatric record for cagrilintide with semaglutide lists it, given subcutaneously5
Pen-injectorA Novo Nordisk crossover study names two pen-injectors, DV3384 and PDS2906
Powder or vialNot stated in the sources retrieved

The FDA says unfamiliarity with drawing from a vial, with confusion between milliliters, milligrams and "units", may have contributed to dosing errors with compounded semaglutide, and a "unit" volume may vary with concentration.7 The mixing guide and the CagriSema calculator show general vial arithmetic only.

Is there a CagriSema label?

Novo Nordisk describes CagriSema 2.4 mg/2.4 mg as an investigational fixed-dose injectable medicine.1 On 18 Dec 2025 it announced the submission of a New Drug Application to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection in adults with obesity, or with overweight and at least one weight-related comorbid condition.1 No FDA decision on the application was among the sources retrieved.

CagriSema doses and schedule in trials

Each trial in the table gave cagrilintide with semaglutide, or a comparator, subcutaneously once weekly, and the trials differ in dose, escalation and length.892101112

TrialDose and schedulePeopleLength
REDEFINE 1 (Garvey, 2025)Cagrilintide 2.4 mg with semaglutide 2.4 mg after a 16-week dose escalation, against semaglutide 2.4 mg, cagrilintide 2.4 mg or placebo138143417 adults without diabetes: 2108 on cagrilintide-semaglutide, 302 on semaglutide, 302 on cagrilintide, 705 on placebo1368 weeks13
REDEFINE 2 (Davies, 2025)Cagrilintide-semaglutide 2.4 mg each, or placebo, assigned 3:1151206 adults with type 2 diabetes: 904 on cagrilintide-semaglutide, 302 on placebo1568 weeks15
Phase 2 (Frias, 2023)0.25 mg once weekly, then 0.5, 1.0 and 1.7 mg at 4-week steps, to 2.4 mg of each from week 17 to week 32, against semaglutide or cagrilintide alone2392 adults with type 2 diabetes: 31 on CagriSema, 31 on semaglutide, 30 on cagrilintide232 weeks3
Phase 1b (Enebo, 2021)Cagrilintide 0.16 to 4.5 mg or matched placebo (3:1), each with semaglutide 2.4 mg, co-escalated in 4-week intervals1096 randomised people aged 18 to 55 with a body-mass index of 27.0 to 39.9 who were otherwise healthy, at a single centre in the USA1016 weeks escalation, 4 at target, 5 follow-up10
REDEFINE 9, phase 3b (Wharton, 2026)Cagrilintide-semaglutide 1.7 mg each (escalated from 0.25 mg each over 12 weeks) or 1.0 mg each (over 8 weeks), or placebo1116309 randomised adults without diabetes: 104 on 1.7 mg each, 103 on 1.0 mg each, 102 on pooled placebo1168 weeks11
REDEFINE 5 (Yamauchi, 2026)Cagrilintide-semaglutide or semaglutide alone (1:1), both escalated to 2.4 mg12331 adults in Japan and Taiwan, with or without type 2 diabetes: 164 on cagrilintide-semaglutide, 167 on semaglutide1268 weeks12

What the semaglutide label says

Novo Nordisk describes CagriSema as cagrilintide 2.4 mg with semaglutide 2.4 mg,1 while the Wegovy label covers semaglutide alone, in single-dose pens of 0.25 mg/0.5 mL up to 2.4 mg/0.75 mL, or 7.2 mg/0.75 mL (Wegovy HD), and in a FlexTouch pen of 9.6 mg/3 mL (3.2 mg/mL) that delivers four 2.4 mg/0.75 mL doses.4 Its Table 1, for all approved indications in adults and pediatric patients aged 12 years and older, starts at 0.25 mg once weekly for 4 weeks, then escalates every 4 weeks.4 After escalation, the label gives a usual maintenance dosage of 2.4 mg once weekly and, for weight reduction in adults, either 1.7 mg or 2.4 mg once weekly, with an increase to a maximum of 7.2 mg once weekly for patients who tolerate 2.4 mg for at least 4 weeks and for whom additional weight reduction is clinically indicated; it also says escalation may be delayed for 4 weeks if a dose is not tolerated.4

How CagriSema is stored

The sources retrieved give no CagriSema storage statement, before or after first use. The Wegovy label (semaglutide alone) stores the single-dose pen or syringe at 2°C to 8°C in the original carton, protected from light; if needed, before cap removal, the pen can be kept at 8°C to 30°C for up to 28 days.4

Frequently asked questions

Where is CagriSema injected?

The EMA's record lists the route as subcutaneous use.5 The sources retrieved give no CagriSema injection site statement.

Can CagriSema be compounded from powder?

The FDA states that cagrilintide cannot be used in compounding under federal law and is not a component of FDA-approved drugs.17

References

  1. Novo Nordisk (press release via BioSpace). Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management. 2025. biospace.com
  2. Lancet (London, England) (PubMed abstract). Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. 2023. pubmed.ncbi.nlm.nih.gov
  3. ClinicalTrials.gov (US National Library of Medicine). NCT04982575: Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes. 2023. clinicaltrials.gov
  4. Novo Nordisk Pharmaceutical Industries, LP via DailyMed (US label). WEGOVY (semaglutide) injection and tablets, US prescribing information. 2026. dailymed.nlm.nih.gov
  5. European Medicines Agency. EMA/PE/0000240529 - paediatric investigation plan | European Medicines Agency (EMA). 2026. ema.europa.eu
  6. ClinicalTrials.gov (US National Library of Medicine). NCT06716307: A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity. 2025. clinicaltrials.gov
  7. US FDA. FDA alerts health care providers, compounders of dosing errors. 2024. fda.gov
  8. Hypertension (Dallas, Tex. : 1979) (full text, PubMed Central). CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. 2025. pmc.ncbi.nlm.nih.gov
  9. ClinicalTrials.gov (US National Library of Medicine). NCT05394519: A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight. 2025. clinicaltrials.gov
  10. Lancet (London, England) (PubMed abstract). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. 2021. pubmed.ncbi.nlm.nih.gov
  11. The lancet. Diabetes & endocrinology (PubMed abstract). Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9). 2026. pubmed.ncbi.nlm.nih.gov
  12. The lancet. Diabetes & endocrinology (PubMed abstract). Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5). 2026. pubmed.ncbi.nlm.nih.gov
  13. The New England journal of medicine (PubMed abstract). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. 2025. pubmed.ncbi.nlm.nih.gov
  14. ClinicalTrials.gov (US National Library of Medicine). NCT05567796: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight. 2026. clinicaltrials.gov
  15. The New England journal of medicine (PubMed abstract). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. 2025. pubmed.ncbi.nlm.nih.gov
  16. ClinicalTrials.gov (US National Library of Medicine). NCT06388187: A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight. 2026. clinicaltrials.gov
  17. US FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2026. fda.gov